| Literature DB >> 32300475 |
Hanna Johansson1,2, Malin Freidle1, Urban Ekman3, Ellika Schalling4,5, Breiffni Leavy1,2,6, Per Svenningsson7, Maria Hagströmer1,2,8, Erika Franzén1,2,6.
Abstract
BACKGROUND: Recent studies indicate that exercise can induce neuroplastic changes in people with Parkinson's disease (PwPD). Reports of feasibility outcomes from existing pilot trials however are, of date, insufficient to enable replication by others in larger definitive trials.Entities:
Year: 2020 PMID: 32300475 PMCID: PMC7132585 DOI: 10.1155/2020/2410863
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Descriptions of intervention and control group.
| Detail | HiBalance, intervention group | HiCommunication, control group |
|---|---|---|
| Setting | Exercise hall | Room for group treatment |
|
| ||
| Personnel | Two physical therapists | One speech and language pathologist |
|
| ||
| Position performed | Standing and walking | Sitting |
|
| ||
| Core areas | (i) Sensory integration | (i) Voice intensity |
| (ii) Anticipatory postural adjustments | (ii) Articulatory precision | |
| (iii) Motor agility | (iii) Word retrieval | |
| (iv) Stability limits | (iv) Memory | |
|
| ||
| Block A, weeks 1-2 | Learning exercises, focus on quality. Single-task performance of exercises pertaining to each core area | Learning exercises, improving speech technique by practicing breathing, phonation, articulation, and increased vocal loudness while maintaining good voice quality |
|
| ||
| Block B, weeks 3–6 | Increased difficulty of exercises by adding cognitive and motor dual tasks | Increased difficulty of exercises by, for example, using memory games and association tasks to increase cognitive load during speech exercises |
|
| ||
| Block C, weeks 7–10 | Complexity increased by combining exercises from all four focus areas and by switching between cognitive and motor dual tasks | Complexity increased by increasing difficulty of memory games, incorporating more interaction between participants, and by adding background noise |
|
| ||
| Home exercise program, performed once a week | Aerobic capacity (e.g., walking or exercise bike) | Relaxation and breathing exercises |
Assessment schedule.
| Outcome domain | Test | Preintervention sessions | Postintervention sessions | ||||||
|---|---|---|---|---|---|---|---|---|---|
| I | II | III | Others | I | II | III | Others | ||
| Balance | Mini-BESTest | √ | √ | ||||||
| ABC-scale | √ | √ | |||||||
|
| |||||||||
| Gait | GAITRite® analysis | √ | √ | ||||||
| Walk 12 | √ | √ | |||||||
|
| |||||||||
| Motor function | MDS-UPDRS part I-III | √ | √ | ||||||
|
| |||||||||
| Physical activity | Accelerometer wear, 7 days | √ | √ | ||||||
|
| |||||||||
| QoL and health status | EQ5D | √ | √ | ||||||
| PDQ-39 | √ | √ | |||||||
| HADS | √ | √ | |||||||
|
| |||||||||
| Global cognition | MoCA | √ | √ | ||||||
|
| |||||||||
| Executive function | Trail making test, trial IV; the color-word interference test; verbal fluency | √ | √ | ||||||
| √ | √ | ||||||||
| √ | √ | ||||||||
| √ | √ | ||||||||
|
| |||||||||
| Attention/working memory | Digit span; trail making test, trials I-III | √ | √ | ||||||
| √ | √ | ||||||||
|
| |||||||||
| Episodic memory | Brief visuospatial memory test; brief visuospatial memory test-revised (BVMT-R) | √ | √ | ||||||
|
| |||||||||
| Visuospatial functions | Copy condition from BVMT-R | √ | √ | ||||||
|
| |||||||||
| Brain structure and function | Magnetic resonance imaging (MRI) | √ | √ | ||||||
| Task functional MRI (fMRI) | √ | √ | |||||||
| Resting state fMRI | √ | √ | |||||||
|
| |||||||||
| Level of BDNF | Blood sample | √ | √ | ||||||
|
| |||||||||
| Voice intensity | Speech recording | √ | √ | ||||||
|
| |||||||||
| Dysarthria | Dysarthria assessment | √ | √ | ||||||
|
| |||||||||
| Acceptability | MRI questionnaire | √ | |||||||
| Intervention follow-up questionnaire | √ | ||||||||
Abbreviations: Mini-BESTest, Mini-Balance Evaluation Systems Test; ABC-scale, Activities-specific Balance Confidence scale; MDS-UPDRS, Movement Disorder Society–Unified Parkinsons Disease Rating Scale; EQ5D, EuroQol 5 dimensions; PDQ-39, Parkinsons Disease Questionnaire -39; HADS, Hospital Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment.
Figure 1Consort flow diagram of participants.
Demographic and clinical characteristics of the participants at baseline.
| Characteristics | HiBalance ( | Control ( |
|---|---|---|
| Age, | 72.0 (60–78) | 67.5 (63–70) |
| Sex, | 1 | 3 |
| LEDD (mg)1 | 700 (380–920) | 765.5 (525–1171) |
| Body mass index, kg/m2 | 23.5 (19.6–25.9) | 24.4 (21.2–26.8) |
| Years with PD | 10.0 (3–13) | 7.0 (3–11) |
| Hoehn and Yahr2, 0–5 | 2 | 2.5 |
| 2, | 5 | 3 |
| 3, | 2 | 3 |
| MDS-UPDRS part III, 0–1323 | 35.0 (24–46) | 32.5 (22–52) |
| Falls in last year, | 0 (0–4) | 0 (0–3) |
| Mini-BESTest, 0–284 | 24.0 (21–27) | 22.5 (19–25) |
| Montreal Cognitive Assessment5 | 27.0 (26–30) | 26.5 (21–28) |
1Levodopa daily equivalent dosage. 2Stages of disease progression from 1 to 5 (1 = minimal disability; 5 = confined to bed/wheelchair). 3Movevement disorder society-unified Parkinson's disease rating scale, motor examination, where lower scores indicate better motor function. 4A 14-item clinical test of balance function (maximum score = 28), where higher scores indicate better balance function. 5Cognitive screening-test scoring from 0 to 30, where higher scores indicate better global cognitive function.
Trends in outcome response.
| Outcome measures | HiBalance | Direction | Control | Direction |
|---|---|---|---|---|
| Physical performance and well-being | ||||
| Mini-BESTest, 0-28a | 0 (−2 to 1) | 0 | 0 (−7 to 1) | 0 |
| Comfortable gait speed, m/sec | 0.05 (−0.20 to 0.15) | + | 0.00 (−0.06 to 0.10) | 0 |
| Dual-task cost on gait speedb, N-Back, % | 1.9 (−9.3 to 22.3) | − | −3.8 (−12.1 to 8.7) | + |
| Dual-task cost on gait speedb, audiostroop, % | −3.0 (−17.7 to 28.6) | + | −6.4 (−26.6 to 8.3) | + |
| PDQ-39 summary index, %c | −8.4 (−32.7 to 1.9) | + | 1.7 (−3.5 to 17.4) | − |
|
| ||||
| Executive function | ||||
| Trail making test, trial 4, secd | 1.0 (−112.0 to 20.0) | − | −28.0 (−82.0 to 16.0) | + |
| Color word interference, trial 3, secd | 2.0 (−7.0 to 17.0) | − | −2.0 (−9.0 to 11.0) | − |
| Color word interference, trial 4, secd | −7.0 (−36.0 to 16.0) | + | 5.0 (−37.0 to 14.0) | − |
| Verbal fluency, | 2.0 (0.0 to 3.0) | + | 1.0 (−3.0 to 6.0) | + |
|
| ||||
| Voice | ||||
| Sound pressure level, dB (C) | 0.0 (−1.7 to 2.3) | 0 | 2.5 (−1.3 to 5.6) | + |
Direction indicates whether trend in change from pre- to postintervention was positive (+), negative (−), or unchanged (0). aA 14-item clinical test of balance function (maximum score = 28), where higher scores indicate better balance function. bDual-task cost on gait speed, where negative values indicate trend to improve and positive values indicate trend to decline. cPDQ-39: Parkinson's Disease Questionnaire-39, consisting of eight subdomains and a summary index, scale between 0 and 100. Summary index scale where 0 indicates perfect health as assessed by the measure and 100 indicates worst health as assessed by the measure. dFrom Delis Kaplan Executive Function System™, negative values indicate trend to improve and positive values indicate trend to decline. eFrom Delis Kaplan Executive Function System™, positive values indicate trend to improve and negative values indicate trend to decline.
Figure 2Absolute values on the Mini-BEST test of individuals (grey lines) and group median values (black lines) for both groups at pre- and postassessment. (a) HiBalance group. (b) Control group.